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Abstract
Background: Spinocerebellar ataxia 17 (SCA17) is one of the most heterogeneous forms of autosomal dominant
cerebellar ataxias with a large clinical spectrum which can mimic other movement disorders such as Huntington
disease (HD), dystonia and parkinsonism. SCA17 is caused by an expansion of CAG/CAA repeat in the Tata binding
protein (TBP) gene. Normal alleles contain 25 to 40 CAG/CAA repeats, alleles with 50 or greater CAG/CAA repeats
are pathological with full penetrance. Alleles with 43 to 49 CAG/CAA repeats were also reported and their penetrance
is estimated between 50 and 80%. Recently few symptomatic individuals having 41 and 42 repeats were reported but
it is still unclear whether CAG/CAA repeats of 41 or 42 are low penetrance disease-causing alleles. Thus, phenotypic
variability like the disease course in subject with SCA17 locus restricted expansions remains to be fully understood.
Case presentation: The patients was a 63-year-old woman who, at 54 years, showed personality changes and
increased frequency of falls. At 55 years of age neuropsychological tests showed executive attention and visuospatial
deficit. At the age of 59 the patient developed dysarthria and a progressive cognitive deficit. The neurological
examination showed moderate gait ataxia, dysdiadochokinesia and dysmetria, dysphagia, dysarthria and abnormal
saccadic pursuit, severe axial asynergy during postural changes, choreiform dyskinesias. Molecular analysis of the TBP
gene demonstrated an allele with 41 repeat suggesting that 41 CAG/CCG TBP repeats could be an allele associated
with the full clinical spectrum of SCA17.
Conclusions: The described case with the other similar cases described in the literature suggests that 41 CAG/CAA
trinucleotides should be considered as critical threshold in SCA17. We suggest that SCA17 diagnosis should
be suspected in patients presenting with movement disorders associated with other neurodegenerative signs
and symptoms.
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Background
Spinocerebellar ataxia 17 (SCA17) is one of the most het-
erogeneous forms of autosomal dominant cerebellar ataxias
with a large clinical spectrum which can mimic other
movement disorders such as Huntington disease, dystonia
and parkinsonism [1, 2]. In addition to gait and limb ataxia
and dysarthria, the clinical picture may include parkinson-
ism, choreic movements, dystonia, cognitive and psychiatric
symptoms. Furthermore, epilepsy and extrapyramidal signs
may be also present [3–5].
Brain magnetic resonance imaging (MRI) usually
shows marked cerebellar atrophy with milder cerebral
atrophy and relative brainstem sparing.
SCA17 is caused by an expansion of CAG/CAA repeat
in the Tata binding protein (TBP) gene [6]. The CAG/
CAA repeat expansion shows intergenerational stability
that may be due to the presence of the CAA interrup-
tion [1, 3, 7]. Normal alleles contain 25 to 40 CAG/CAA
repeats while 50 or greater CAG/CAA repeats are alleles
with full penetrance [8]. Alleles with 43 to 49 CAG/
CAA repeats were also reported and their penetrance is
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estimated between 50 and 80%. It is still unclear whether
CAG/CAA repeats of 41 or 42 are low penetrance dis-
ease-causing alleles, nevertheless few symptomatic in-
dividuals having 41 and 42 repeats were reported
recently [9–11].
Herein we report a patient carrying 41 CAG/CAA re-
peats presenting with the SCA17 classical features.
Case presentation
The proband was a 63-year-old woman who suffered of
a severe depressive episode at 46 years of age, then she
slowly developed gait ataxia with falls and dysfunction of
fine finger movements. She is the second child of unre-
lated Italian parents. The father died at 82 years of age
with cognitive deterioration starting at 70; the mother is
87 years old and healthy. The patient has three healthy
siblings and a son (34 years old) who is reported to suf-
fer of epilepsy since his childhood and showing a wide-
based gait in the last two years.
When she was 54, the patient’s relatives noticed per-
sonality changes (aggressiveness, hyperphagia, inappro-
priate shopping) and increased frequency of falls. Brain
magnetic resonance imaging (MRI) showed bilateral and
symmetric moderate atrophy of frontal and parietal cor-
tex and clear atrophy of both cerebellum hemispheres
and vermis. At that time a tentative diagnosis of olivo-
ponto-cerebellar atrophy was made in another hospital.
At 55 years of age neuropsychological tests (including
Stroop color-word, Wisconsin Card Sorting, Rey audi-
tory verbal learning, Clock drawing, Digit symbol, and
Trail Making A and B tests) showed executive attention
and visuospatial deficit. The mini-mental state examin-
ation (MMSE) score was 29/30. At the age of 59 the
patient developed dysarthria. When she was 61 she
suffered from generalized tonic-clonic seizures but the
interictal electroencephalogram (EEG) was normal.
There was progressive cognitive worsening and at the
age of 62 the neuropsychological assessment showed
deficit in verbal memory, language and attention, and
the MMSE scored 15/30. The neurological examination
showed moderate gait ataxia, dysdiadochokinesia and
dysmetria, dysphagia, dysarthria and abnormal saccadic
pursuit, severe axial asynergy during postural changes,
choreiform dyskinesias involving upper limbs, face, and
tongue. She had no muscle weakness or sensory deficits,
deep tendon reflexes were normal and pyramidal signs
were absent. At the time of the last examination when
the patient was 63, she required assistance for everyday
activities. Brain MRI showed advanced cerebellar atro-
phy, involving both hemispheres and vermis, with brain-
stem sparing (Fig. 1a). Brain single photon emission
computed tomography (SPECT) using the Dopamine
Transporter (DAT) ligand I-123 Ioflupane (DAT-SPECT)
showed mild reduced uptake in left posterior putamen
but was otherwise normal (Fig. 1b). F-18 Fluorodeoxyglu-
cose positron emission tomography (FDG-PET) showed
severely decreased glucose metabolism of both cerebellar
hemispheres and putamen (Fig. 1c).
Molecular analysis methods
The genetic analysis for HD, DRPLA and TBP was per-
formed on genomic DNA extracted from peripheral blood
sample by standard methods. The polymerase chain reac-
tion (PCR) was performed by using the published primers
[6] and PCR products were separated by capillary electro-
phoresis ABIPrism 3130XL Genetic Analyzer. The size of
each allele was established by comparison with control
DNAs previously determined by direct sequencing.
Fig. 1 a Sagittal brain MRI (T2-weighted) disclosing gross and diffuse atrophy involving the cerebellum (A). Coronal brain MRI (T1-weighted) showing
symmetrical atrophy of cerebellum and parietal cortex (B). Axial brain MRI (FLAIR) showing preservation of basal ganglia (C). b DAT-SPECT with I-123
ioflupane showed globally normal standardized binding ratios with only mild reduction of the putamen-to-caudate ratio in the left hemisphere (0.64).
Semi quantification was achieved through the Basal ganglia software V2 (Calvini et al., [15]). c 18F- FDG PET showed severely decreased uptake in both
cerebellar hemispheres (A) and moderate decreased uptake in the two putamen, mainly in the left hemisphere (B). No cortical uptake deficit was found
(B, C). Hot colors (white, red, yellow) report higher uptake than cold colors (green, blue)
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Results
Routine laboratory investigations, including serum ana-
lysis of copper, ceruloplasmine, thyroxine and blood
count, including test for acantocytosis were normal.
Other causes of choreic syndromes (vascular/infectious,
vitamin deficiencies, and metabolic disorders) were
excluded. Molecular genetic testing for Huntington’s
disease, dentatorubral-pallido-luysian atrophy, SCA1,
SCA2, SCA3, SCA6, SCA7 were previously excluded in
another laboratory. Informed consent for genetic testing
was signed by the patient and by her sister (legal tutor).
Genetic analysis of the TBP showed two alleles of 36
and 41 CAG/CAA repeats. The analysis of TBP gene
was repeated with matching results in one more labora-
tory, in blind.
Discussion
Few SCA17 patients having 41 CAG/CCG have been re-
ported so far, Nanda et al. [9] reported a patient with a
prominent cerebellar involvement and a mild cognitive
impairment with onset at age 50 years. Doherty et al.
[12] reported a patient presenting at 59 years with late
onset ataxia mimicking multiple system atrophy type C
(MSA-C). Park et al. [13] described a patient presenting
with parkinsonism and chorea with onset at age 61 years
in whom the PET scan performed eight years after onset
showed marked decrease of dopamine transporter
(DAT) density in the bilateral putamen. Alibardi et al.
[11] reported a patient with psychiatric onset and late
chorea without cerebellar and pyramidal involvement.
As in our patient, in all these cases the diagnosis of
SCA17 took some years and was performed only after
excluding other acquired and genetic causes of move-
ment disorders.
The wide clinical spectrum of SCA17 is challenging
for diagnosis. In these patients, in spite of the same
number of CAG/CCG which they carried, both the type
of symptoms and signs at onset and the disease course
are different, as shown in Table 1.
Moreover, probably because of the low number of TBP
repeats associated with incomplete penetrance, the family
history is often negative and therefore useless. In the
present case, a near-normal DAT SPECT with a full-
blown clinical picture virtually rules out both Parkinson’s
disease and MSA, although some degree of reduced DAT
uptake has been reported in SCA 17 patients as well [14].
There have been few case reports of patients with a
typical phenotype and 41 repeats, suggesting a moderate
disease course [9–11, 13], which is not the case with our
patient. Despite our patient carried 41 repeat expansion,
she developed a typical phenotype with chorea and
early-onset dementia. Thus, phenotypic variability like
the disease course in subject with SCA17 locus re-
stricted expansions remains to be fully understood.
Conclusions
We believe that 41 CAG/CCG TBP repeats is an allele
which can be associated with the full clinical spectrum
of SCA17, although with incomplete penetrance. The
described case with the other similar cases described in
the literature suggests that 41 CAG/CAA trinucleotides
should be considered as critical threshold in SCA17.
These findings support the idea that a degree of CAG/
CAA repeats correlate with penetrance but not the
phenotype variability. Therefore, due to pleiotropic ef-
fects of TBP gene, we suggest that SCA17 diagnosis
should be suspected in patients presenting with move-
ment disorders associated with other neurodegenerative
signs and symptoms.
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